Summary of in vitro inhibition data for CYP1A2, CYP2C9, CYP2C19, and CYP2D6 for 27 drugs Values represent the mean ± S.E. When IC50 was greater than 300 μM, the percent inhibition value at 300 μM was included (in parentheses).
Drug | IC50 | ||||||
|---|---|---|---|---|---|---|---|
| CYP1A2 | CYP2C9 | CYP2C19 | CYP2D6 | ||||
| μM | |||||||
| Cimetidine | >300 (16%) | >300 (22%) | 100 ± 10 | 130 ± 10 | |||
| Citalopram | >300 (7%) | >300 (20%) | >300 (41%) | 30 ± 3 | |||
| Clarithromycin | >300 (8%) | >300 (4%) | >300 (11%) | >300 (6%) | |||
| Dicumarol | ND | 0.21 ± 0.01 | ND | ND | |||
| Diltiazem | >300 (4%) | >300 (53%) | 170 ± 10 | >300 (43%) | |||
| Diphenhydramine | ND | ND | ND | 12 ± 1 | |||
| Disulfiram | 1.3 ± 0.3 | 0.96 ± 0.32 | 5.5 ± 1.1 | 12 ± 2 | |||
| Enoxacin | 220 ± 20 | ND | ND | ND | |||
| Erythromycin | >300 (9%) | >300 (6%) | >300 (16%) | >300 (4%) | |||
| Fluconazole | >300 (17%) | 11 ± 1 | 5.8 ± 0.2 | 170 ± 20 | |||
| Fluoxetine | 240 ± 70 | 33 ± 6 | 14 ± 2 | 0.27 ± 0.02 | |||
| Fluvoxamine | 0.035 ± 0.003 | 6.1 ± 0.2 | 0.35 ± 0.01 | 5.2 ± 0.7 | |||
| Ketoconazole | 25 ± 9 | 5.9 ± 0.6 | 9.4 ± 1.2 | 28 ± 6 | |||
| Metronidazole | >300 (12%) | >300 (0%) | >300 (1%) | >300 (0%) | |||
| Moclobemide | ND | ND | 160 ± 5 | ND | |||
| Nefazodone | 52 ± 15 | 17 ± 2 | 20 ± 5 | 11 ± 2 | |||
| Paroxetine | 8.4 ± 0.5 | 130 ± 20 | 22 ± 4 | 0.32 ± 0.02 | |||
| Propranolol | 17 ± 2 | >300 (18%) | 79 ± 16 | 6.6 ± 0.2 | |||
| Quinidine | ND | ND | ND | 0.058 ± 0.004 | |||
| Ranitidine | >300 (0%) | >300 (5%) | >300 (8%) | >300 (16%) | |||
| Risperidone | >300 (3%) | 280 ± 20 | 290 ± 30 | 12 ± 1 | |||
| Roxithromycin | >300 (4%) | >300 (1%) | >300 (5%) | 250 ± 50 | |||
| Sertraline | 13 ± 2 | 81 ± 19 | 4.2 ± 0.6 | 1.8 ± 0.1 | |||
| Sulfaphenazole | ND | 0.28 ± 0.03 | ND | ND | |||
| Terbinafine | 12 ± 1 | >300 (33%) | 17 ± 4 | 0.041 ± 0.002 | |||
| Ticlopidine | 11 ± 1 | 110 ± 10 | 0.78 ± 0.15 | 4.0 ± 0.5 | |||
| Troleandomycin | 300 (10%) | >300 (16%) | >300 (17%) | >300 (16%) | |||
ND, not determined.